Published Articles

Cutting the Cost of South African Antiretroviral therapy using newer, safer drugs. View


24 July 2019: Global HIV Treatment — Turning Headwinds to Tailwinds View
24 July 2019: Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1 View
24 July 2019: Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV View
29 May 2019: Moorhouse MA, Cohen K. The role of rilpivirine in Southern Africa. S Afr J HIV Med. 2019;20(1), a825. View


27 March 2018: £3 million boost for Liverpool advances materials and healthcare research. View
17 July 2018: Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. S Afr J HIV Med. 2018;19(1), a817. View
5 January 2018. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science. 05 Jan 2018: Vol 359, Issue 6371, pp. 86-90. DOI: 10.1126/science.aam8825. View
24 January 2018. NIH begins large HIV treatment study in pregnant women 3 View
25 January 2018. PEPFAR – 15 Years and Counting the Lives Saved. N Engl J Med 2018: 378:314-316. DOI: 10.1056/NEJMp1714773. View
Effect of dolutegravir in combination with nucleoside reverse transcriptase inhibitors on people living with HIV who have pre-existing nucleoside reverse transcriptase inhibitor mutations. Sörstedt, E et al. International Journal of Antimicrobial Agents. DOI: View One View Two
6 August 2018: Pharmacokinetics of Efavirenz 400mg Once Daily Coadministered with Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. Clinical Infectious Diseases , ciy491 View


C Serenata, H Gous, J Grab, M Moorhouse, E Maharaj. Optimising ART in the 21st Century. HIV Nursing Matters. Publication in May 2017. View
FOA Nabeemeeah, T Masemola, MA Moorhouse. Dolutegravir: The game changer? HIV Nursing Matters. Publication in May 2017. View
31 August, Lancet Commentary: The triumph of HIV treatment: another new antiretroviral. Commentary from Marta Boffito and Francois Venter. View
The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. JIAS. View
Andrew Hill, Francois Venter. 2017. The unexpected success of NRTIs in second-line treatment. The Lancet Infectious Diseases. Published online November 3, 2017. View


28 December 2016: South African Medical Journal: Cutting the cost of South African antiretroviral therapy using newer, safer drugs. View
July edition of Current Opinion in HIV and AIDS for several articles on ART optimisation,
  • The ADVANCE study: a ground breaking trial to evaluate a candidate universal antiretroviral regimen – Francois Venter, Polly Clayden and Celicia Serenata
  • When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank – Marco Vitoria, Nathan Ford, Polly Clayden, Anton Pozniak, and Andy Hill